Evolutionary Conservation of Long Non-coding RNAs in Non-Alcoholic Fatty Liver Disease

The authors give a comprehensive catalogue of well reported lncRNAs in non-alcoholic fatty liver disease (NAFLD) and classify them using sequence and synteny-based evolutionary conservation across rodents, nonhuman primate and human species.
[Life Sciences]
Rohilla, S., Awasthi, A., Kaur, S., & Puria, R. (2020). Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease. Life Sciences, 118560. https://doi.org/10.1016/j.lfs.2020.118560 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva announced that the FDA has granted Breakthrough Therapy designation to lanifibranor, the company’s lead drug candidate, for the treatment of NASH.
[Inventiva]
Press Release
Bookmark

No account yet? Register

0
Share

Understanding Lipotoxicity in NAFLD Pathogenesis: Is CD36 a Key Driver?

Investigators provide succinct insights into the molecular mechanisms responsible for lipotoxicity in non-alcoholic fatty liver disease (NAFLD), including ER and oxidative stress, autophagy, lipoapotosis and inflammation. They highlight the role of CD36/FAT fatty acid translocase in NAFLD pathogenesis.
[Cell Death & Disease]
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020). Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death & Disease, 11(9), 1–15. https://doi.org/10.1038/s41419-020-03003-w Cite
Full Article
Bookmark

No account yet? Register

0
Share

Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output

Scientists observed that Steatohepatitis-associated circRNA ATP5B Regulator (SCAR), which is located in mitochondria, inhibited mitochondrial ROS output and fibroblast activation.
[Cell]
Zhao, Q., Liu, J., Deng, H., Ma, R., Liao, J.-Y., Liang, H., Hu, J., Li, J., Guo, Z., Cai, J., Xu, X., Gao, Z., & Su, S. (2020). Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output. Cell, 0(0). https://doi.org/10.1016/j.cell.2020.08.009 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

89bio Announces Positive Topline Results from its Phase Ib/IIa Trial of BIO89-100 in NASH

89bio, Inc. has announced positive topline results from its Phase Ib/IIa trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH).
[89bio, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population

Theratechnologies Inc. has announced that it plans to pursue Phase III clinical development of tesamorelin for the treatment of non-alcoholic steatohepatitis (NASH) in the general population.
[Theratechnologies Inc. (GloveNewswire Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

The Times They are A-Changin’ (For NAFLD as well)

Diseases like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) bring a very high level of pathogenic complexity and far-reaching implications that apply not only scientists but also to clinicians, patients, regulators, bio-pharmaceutical industry and third-party payers.
[Journal of Hepatology]
Ratziu, V., Rinella, M., Beuers, U., Loomba, R., Anstee, Q. M., Harrison, S., Francque, S., Sanyal, A., Newsome, P. N., & Younossi, Z. (2020). The times they are a-changin’ (for NAFLD as well). Journal of Hepatology, 0(0). https://doi.org/10.1016/j.jhep.2020.08.028 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial

Madrigal Pharmaceuticals, Inc. announced that it has already exceeded the originally targeted enrollment of 700 patients in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with NASH and fibrosis that is diagnosed using non-invasive assessments.
[Madrigal Pharmaceuticals, Inc. (GlobeNewswire)]
Press Release
Bookmark

No account yet? Register

0
Share

Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases

Engitix Ltd is developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform. They have entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company Ltd. to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
[Engitix Ltd. ]
Press Release
Bookmark

No account yet? Register

0
Share

Boston Pharmaceuticals Licenses Potential NASH Treatment from Novartis

Two years after nabbing three novel anti-infective drug candidates from Swiss pharma giant Novartis for the treatment of antibiotic-resistant infections, Boston Pharma struck another deal, this time for a potential treatment for Non-Alcoholic Steatohepatitis (NASH).
[Boston Pharmaceuticals (BioSpace)]
Press Release
Bookmark

No account yet? Register

0
Share

Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver

Scientists demonstrated that Kupffer cells (KCs) were reduced in metabolic-associated fatty liver disease, being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated macrophages from obese adipose tissue.
[Immunity]
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., Prijck, S. D., Vanhockerhout, M., Latib, M. B. A., Devisscher, L., Hoorens, A., Bonnardel, J., Vandamme, N., Kremer, A., Borghgraef, P., Vlierberghe, H. V., Lippens, S., … Scott, C. L. (2020). Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2020.08.004 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share